Pantoprazole-Hetero gastro-resistant tablets 40 mg blister No. 30

Pantoprazole-Hetero gastro-resistant tablets are prescribed for the following indications:

Composition

Active ingredient: pantoprazole;

1 tablet contains 20 mg or 40 mg of pantoprazole (as pantoprazole sodium sesquihydrate);

Excipients: lactose, hydroxypropylcellulose, calcium stearate, sodium carbonate anhydrous, sodium lauryl sulfate, coating: hypromellose, iron oxide yellow (E 172), propylene glycol, titanium dioxide (E 171), methacrylate copolymer (type A), triethyl citrate, polysorbate 80, black ink (S-1-17823).

Contraindication

Hypersensitivity to the active substance, benzimidazole derivatives and components of the drug.

Method of application

Pantoprazole-Hetero, gastro-resistant tablets, are swallowed whole, regardless of food intake. Patients who cannot swallow a 40 mg tablet whole are prescribed two 20 mg tablets. Concomitant administration of antacids does not affect the absorption of Pantoprazole-Hetero, gastro-resistant tablets.

Application features

Pregnant women

Prescribe only when absolutely necessary.

Children

The drug Pantoprazole-Hetero is recommended for short-term treatment of EE associated with GERD in patients over 5 years of age.

Drivers

With caution.

Overdose

Experience with very high doses of pantoprazole (> 240 mg) in patients is limited. The available data on overdose were generally consistent with the known safety profile of pantoprazole. Pantoprazole is not removed from the body by hemodialysis. In case of overdose, symptomatic and supportive treatment is prescribed.

Side effects

Metabolism and metabolic disorders: Rarely hyperlipidemia and increased lipid levels (triglycerides, cholesterol), changes in body weight, increased CPK levels, generalized edema.

Gastrointestinal: Uncommon: Clostridium difficile-associated diarrhea, nausea, vomiting, abdominal distension, constipation, dry mouth, abdominal pain and discomfort.

Interaction

Concomitant administration of atazanavir or nelfinavir with proton pump inhibitors is not recommended, as this may result in decreased plasma concentrations of atazanavir or nelfinavir, leading to decreased therapeutic effect and development of resistance.

Storage conditions

Store at a temperature not exceeding 25 °C in the original packaging, out of the reach of children.

Shelf life - 2 years.